IGF2 and prostate carcinoma: In the placebo arm, above median serum 25(OH)D levels were associated with increased risk of prostate cancer among men with higher IGF-2 (OR:1.33, 95% CI: 1.00–1.65), with a significant interaction between 25(OH)D and treatment arm (Pinteraction = 0.04).